News | November 05, 2006

Protective Effects of MC-1 Shown in CABG Patients

Results from the Phase II MEND-CABG study — which looked at demonstrated the clinical benefits of MC-1 in reducing cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery — will be presented during the 2006 Scientific Sessions of the American Heart Association (AHA), to be held Nov. 12-15, 2006 in Chicago.

Medicure Inc., the cardiovascular-focused biopharmaceutical company that produced MC-1, says the study, which included 901 patients and was completed this year, will be presented by Dr. Michel Carrier, director of Cardiovascular Surgery Program, Montreal Heart Institute (MHI) between 3 and 4:30 p.p. Central Time, Sunday Nov. 12 in a poster session in Hall A2 of the McCormick Place Convention Center.

The abstract is titled, "Protective Effect of Pyridoxal-5-phosphate on Perioperative Myocardial Infarction is not Dependent of Aortic Cross Clamp Time: Results from the MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Trial.”

Related Content

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Overlay Init